Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088231 · ClinicalTrials.gov registry record · Phase 1
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00088231: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00088231 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088231, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest safe doses of PTK 787 (vatalanib) and Gleevec (imatinib mesylate) that can be given to treat Chronic Myelogenous Leukemia-Blastic Phase (CML-BP), Refractory Acute Myelogenous Leukemia (AML), or Agnogenic Myeloid Metaplasia (AMM). Another goal is to see how effective this combination treatment is.
Interventions
- DRUG Imatinib Mesylate (Gleevec)
- DRUG PTK 787 (vatalanib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088231
The ClinicalTrials.gov registry entry for NCT00088231 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imatinib Mesylate (Gleevec) is the first listed.
NCT00088231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088231 about?
NCT00088231 is a clinical study titled "PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP". The goal of this clinical research study is to find the highest safe doses of PTK 787 (vatalanib) and Gleevec (imatinib mesylate) that can be given to treat Chronic Myelogenous Leukemia-Blastic Phase (CML-BP), Refractory Acute Myelogenous Leukemia (AML), or Agnogenic Myeloid Metaplasia (AMM). Anothe...
What is the current status of trial NCT00088231?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2004-07. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00088231?
The interventions under investigation include: Imatinib Mesylate (Gleevec) (DRUG), PTK 787 (vatalanib) (DRUG).
Who is sponsoring clinical trial NCT00088231?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.